Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 24.96

+1.1%

10:18 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (1608)	9/30/1999 11:01:00 PM
From: Danny Hayden	Read Replies (1) of 1722

Stocks to watch Friday Eli Lilly gets FDA nod for osteoporosis drug; Sipex, Cidco, unveil profit warnings September 30, 1999: 6:57 p.m. ET NEW YORK (CNNfn) - Eli Lilly Corp. received government approval to sell a drug that treats osteoporosis -- a disease that thins bones and makes them brittle, the drug maker announced after the bell Thursday. Circuit maker Sipex Corp. and telephone accessories producer Cidco Corp., meantime, both unveiled profit warnings. Eli Lilly Corp. The U.S. Food and Drug Administration said Eli Lilly Corp.'s (LLY) drug Evista can now be used to treat, not just prevent, osteoporosis, the company said. The FDA granted approval to sell the drug as a treatment for women with osteoporosis who have already gone through menopause, an agency spokeswoman told Reuters. The drug has been sold as a preventative medication in the U.S. since January 1998. Evista generated $66.6 million in sales for Eli Lilly in July, according to the company. Eli Lilly was at 64-1/2 after hours. The stock gained 3/4 during the regular session.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next